Laddar...
CSIG-17. PRMT5 INHIBITION SENSITIZES GLIOBLASTOMA MODELS TO TRAMETINIB TREATMENT
INTRODUCTION: Glioblastoma (GBM) is the most common malignant primary brain tumor. With limited effective therapeutic strategies, prognosis for GBM is very poor. Our previous study shows that the expression of Protein Arginine Methyltransferase 5 (PRMT5) is upregulated in GBM; its inhibition promote...
Sparad:
| I publikationen: | Neuro Oncol |
|---|---|
| Huvudupphovsmän: | , , , , , , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Oxford University Press
2020
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7650434/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.129 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|